Enovis (ENOV) Income from Non-Controlling Interests (2012 - 2026)
Enovis' (ENOV) quarterly Income from Non-Controlling Interests came in at $314000.0 in Q2 2026, up 20.31% year-on-year from $261000.0 in Q2 2025, and up 132.59% on a QoQ basis from $135000.0 in Q4 2025.
Enovis (ENOV) Income from Non-Controlling Interests (2012 - 2026) Analysis & Trends
Enovis (ENOV) has 15 years of Income from Non-Controlling Interests data on file, last reported at $314000.0 in Q2 2026.
- On a quarterly basis, Income from Non-Controlling Interests rose 20.31% year-over-year to $314000.0 in Q2 2026; TTM through Apr 2026 was $873000.0, a 11.49% increase from a year earlier, with the FY2025 full-year figure at $820000.0, up 20.77% from the prior year.
- Income from Non-Controlling Interests for Q2 2026 stood at $314000.0, up from $135000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for ENOV reached as high as $314000.0 in Q2 2026 and fell as low as $34000.0 in Q4 2022.
- Historically, Income from Non-Controlling Interests has averaged $176266.7 across 5 years, with a median of $182000.0 in 2023.
- Across the five-year window, Income from Non-Controlling Interests sank 84.26% in 2022 and soared 547.5% in 2024, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $34000.0 in 2022, then surged by 241.18% to $116000.0 in 2023, then advanced by 18.1% to $137000.0 in 2024, then dropped by 1.46% to $135000.0 in 2025, then jumped by 132.59% to $314000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $314000.0 in Q2 2026, $135000.0 in Q4 2025, and $233000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 22.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -5.85 Mn |
| 10 | Enovis | 1.61 Bn | 1.58 Bn | 365.49 Mn | 314,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 314,000.00 |
| Dec 31, 2025 | 135,000.00 |
| Oct 3, 2025 | 233,000.00 |
| Jul 4, 2025 | 191,000.00 |
| Apr 4, 2025 | 261,000.00 |
| Dec 31, 2024 | 137,000.00 |
| Sep 27, 2024 | 259,000.00 |
| Jun 28, 2024 | 126,000.00 |
| Mar 29, 2024 | 157,000.00 |
| Dec 31, 2023 | 116,000.00 |
| Sep 29, 2023 | 40,000.00 |
| Jun 30, 2023 | 182,000.00 |
| Mar 31, 2023 | 192,000.00 |
| Dec 31, 2022 | 34,000.00 |
| Apr 1, 2022 | 267,000.00 |
| Dec 31, 2021 | 216,000.00 |
| Oct 1, 2021 | 191,000.00 |
| Jul 2, 2021 | 705,000.00 |
| Apr 2, 2021 | 876,000.00 |
| Dec 31, 2020 | -1.55 Mn |